Mitochondrial F-ATP Synthase and Its Transition into an Energy-Dissipating Molecular Machine by Lippe, Giovanna et al.
Review Article
Mitochondrial F-ATP Synthase and Its Transition into an
Energy-Dissipating Molecular Machine
Giovanna Lippe , Gabriele Coluccino, Marco Zancani, Walter Baratta, and Paola Crusiz
Department of Agricultural, Food, Environmental and Animal Sciences, University of Udine, Italy
Correspondence should be addressed to Giovanna Lippe; giovanna.lippe@uniud.it
Received 25 January 2019; Accepted 18 March 2019; Published 15 April 2019
Guest Editor: Ulrike Hendgen-Cotta
Copyright © 2019 Giovanna Lippe et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The mitochondrial F-ATP synthase is the principal energy-conserving nanomotor of cells that harnesses the proton motive force
generated by the respiratory chain to make ATP from ADP and phosphate in a process known as oxidative phosphorylation. In the
energy-converting membranes, F-ATP synthase is a multisubunit complex organized into a membrane-extrinsic F1 sector and a
membrane-intrinsic FO domain, linked by central and peripheral stalks. Due to its essential role in the cellular metabolism,
malfunction of F-ATP synthase has been associated with a variety of pathological conditions, and the enzyme is now considered
as a promising drug target for multiple disease conditions and for the regulation of energy metabolism. We discuss structural
and functional features of mitochondrial F-ATP synthase as well as several conditions that partially or fully inhibit the coupling
between the F1 catalytic activities and the FO proton translocation, thus decreasing the cellular metabolic efficiency and
transforming the enzyme into an energy-dissipating structure through molecular mechanisms that still remain to be defined.
1. Introduction
Mitochondria are highly dynamic enclosed organelles har-
bouring an outer membrane (OMM) and an inner mem-
brane (IMM) with a small intermembrane space separating
them. The surface of the IMM is significantly bigger than that
of the OMM due to the presence of numerous invaginations
called cristae that extend more or less deeply into the protein-
dense central matrix [1]. In differentiated aerobic cells, mito-
chondria are crucial for ATP production from nutrient oxi-
dation; for ROS (reactive oxygen species) production,
which contributes to mitochondrial damage in several
pathologies and to redox signalling from the organelle to
the rest of the cell [2, 3]; for intracellular calcium signalling;
and for execution of cell death among other functions [4].
This functional versatility is matched by their great variabil-
ity in number and structure depending on the tissue and
the developmental stage. Mitochondria interact with the
cytoskeleton, which modulates their subcellular localization
and motility, and with the endoplasmic reticulum for
calcium homeostasis. ATP is produced from ADP and
phosphate (Pi) by the F-type ATP synthase complex (or
complex V) in a process known as oxidative phosphoryla-
tion, which takes place in the IMM. The four complexes of
the respiratory chain carry out a series of redox reactions,
resulting in oxygen reduction to water, which are able to sus-
tain the proton-pumping activity of complexes I, III, and IV.
These latter generate an electrochemical gradient across the
IMM known as proton motive force, which is absolutely nec-
essary for F-ATP synthase to produce ATP [5]. From the
intermembrane space, however, protons may leak back to
the mitochondrial matrix independent of ATP synthesis,
decreasing the metabolic efficiency and giving rise to mito-
chondrial uncoupling. In the last decade, there has been a
growing interest in characterizing the endogenous dissipat-
ing pathways, as well as in the chemical agents able to induce
a mild mitochondrial uncoupling, which may provide a pow-
erful therapeutic treatment for widespread diseases such as
obesity and diabetes [6, 7]. This review is especially dedicated
to F-ATP synthase and its transition into an energy-
dissipating enzyme through molecular mechanisms that still
remain to be defined.
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2. F-Type ATP Synthase as a Molecular Motor
The complex structure and the unique functional mechanism
of F-ATP synthase are now known thanks to more than 50
years of studies by several researchers, including the three sci-
entists that were awarded the Nobel Prize: Sir Peter Mitchell,
who demonstrated that F-ATP synthase relies on the elec-
trochemical gradient to perform catalysis [5]; Sir John E.
Walker, who solved the mammalian F-ATP synthase struc-
ture [8]; and Paul Boyer, who clarified the mechanism of
rotational catalysis [9]. Nevertheless, some aspects of the
coupling mechanism between proton translocation and
catalysis remain to be fully understood [10].
In all energy-converting membranes, F-ATP synthase
consists of a roughly globular, water-soluble F1 head and a
membrane-embedded FO subcomplex comprising the a sub-
unit and a ring of multiple c subunits. These moieties are
connected by two stalks: the lateral or peripheral stalk, which
is structurally part of the FO moiety, and the central stalk,
which is associated to the F1 sector [10]. All types of F-
ATP synthases function as nanometer-scale rotary machines
consisting of two motors linked by a rotor, which comprises
the c-ring and the central stalk. One motor located in the FO
sector generates movement of the rotor at a rate of ~100
revolutions/s by consuming the proton motive force; the
other, located in the F1 moiety, uses energy transmitted by
the rotor to synthesize ATP. The synthetic motor can work
in reverse, driving the rotor backward with energy from
ATP, releasing ADP and phosphate, and generating a mem-
brane potential [1]. The strict correlation between proton
flux and rotor rotation has been confirmed by measurement
of the H+ :ATP ratio in a bacterial F-ATP synthase, where a
“perfect chemomechanical coupling” between proton trans-
location, rotary motion, and ATP synthesis/hydrolysis has
been reported, excluding “slip” of the rotor, i.e., rotation of
the c-ring without carrying a proton [11]. This coupling is
instead disrupted by the antibiotic oligomycin, which binds
the c-ring, preventing it to rotate in either directions [12].
Our understanding of how the enzyme works has greatly
come from single-molecule studies, which allowed direct
visualization by fluorescence microscopy of rotating bacte-
rial F-ATP synthases driven by ATP hydrolysis [13] and,
more recently, from electron cryomicroscopy analysis of
mitochondrial and bacterial ATP synthases, revealing the
architecture of the FO sector and thus the mechanisms of
proton translocation [14].
In its simplest bacterial form, the FO sector consists of 9-
15 copies of the subunit c, two copies of the subunit b, and a
copy of the subunit a [14]. While the b subunits constitute
part of the peripheral stalk [15], the subunit a is embedded
in the membrane, where it is organized into a four-helix hor-
izontal bundle that wraps around the c-ring, forming two
semichannels through which the H+ flow by protonation/de-
protonation of conserved carboxylic residues present in each
c subunit [16–18]. The eukaryotic FO sector is made up of
subunits A6L, e, f, and g and 2 or 3 other additional subunits
(DAPIT and 6.8PL in vertebrates; i/j, k, and l in yeast),
besides subunits a, b, and c [14]. The smaller c-ring, which
comprises 8 or 10 c subunits in metazoans and yeast, lowers
the bioenergetic cost of ATP synthesis, i.e., the H+/ATP stoi-
chiometry from 3.3 to 2.7, respectively [19].
The peripheral stalk tends to diverge throughout evolu-
tion, even though the overall structure seems to be constant
[15]. The bacterial peripheral stalk consists of the b2 dimer,
which spans the whole enzyme, and a single copy of the sub-
unit δ. Like the FO membrane-embedded part, the eukaryotic
peripheral stalk is more complex. Its membrane distal part is
constituted by one copy of the subunits b, F6, d, and OSCP
(oligomycin-sensitivity conferral protein, homologous to
the bacterial δ subunit) [20], while its base comprises the
C-terminal region of subunit A6L [18, 21], the N-terminal
domain of the subunit f [18], and the subunit i/j in yeast [22].
F1 is the catalytic sector, which is always composed of
three αβ dimers that alternate in surrounding the central
stalk. The latter comprises the γ subunit, which is associated
with the subunit ε in bacteria and with the subunits δ and ε in
eukaryotes [10] (Figure 1). Indeed, the bacterial ε subunit is
homologous to the mitochondrial δ subunit, whereas the
mitochondrial ε subunit has no equivalent in the bacterial
enzyme [10]. The catalytic nucleotide binding sites are
located in the three β subunits at the interfaces with the
respective three α subunits. According to Boyer’s catalysis
model, subunit γ rotation within α3β3 takes each of the three
β subunits through three major functional conformations,
denoted βE (empty), βDP (bound to ADP), and βTP (bound
to ATP), thereby synthesizing three Mg2+-ATP molecules
during each 360° rotation. During ATP hydrolysis, the tran-
sition between βE, βTP, and βDP states drives the opposite
rotation of the γ subunit and the c-ring, thereby causing the
formation of a proton gradient. In both ATP synthetic and
hydrolytic directions, Mg2+ is essential for catalysis [10].
Due to its complexity, the F-ATP synthase assembly
occurs in a modular fashion to prevent formation of interme-
diates that could depolarize the membrane or waste ATP
[23], although the pathways are still debated [24]. The struc-
tural and functional coupling between FO and F1 in the
mature complex is mainly guaranteed by the OSCP or δ sub-
unit in mitochondria and in bacteria, respectively. Through
its contacts with both the α3β3 hexamer and the peripheral
stalk, OSCP or δ prevents corotation of the αβ dimers with
the γ subunit, thereby ensuring very high enzyme efficiency
[25]. Another domain crucial for the functional coupling is
located at the C-terminus of β subunit, which is in direct con-
tact with γ subunit, termed the DELSEED loop, which is
thought to transfer the torque to γ from the nucleotide bind-
ing domain [26]. Moreover, in mitochondria, the high cata-
lytic efficiency of F-ATP synthase seems to be mediated
also by formation of the V-shaped dimers [27, 28]. The elec-
tron cryomicroscopy maps of the mammalian [29] and yeast
[18] enzymes revealed that subunits e and g, with the N-
terminal part of subunit b and probably of subunit k in yeast,
create in the F-ATP synthase monomers a subdomain that
bends the IMM. These bends would drive self-assembly of
the monomers into V-shaped dimers. Then, dimers self-
assemble into long rows of oligomers localized at the cristae
ridges [30] to maintain the typical IMM morphology [31].
The mitochondrial cristae would act as proton traps, favour-
ing effective ATP synthesis by F-ATP synthase localized at
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the apex. Electron cryotomography showed that the dimers
are organized in situ with the peripheral stalks turned away
from one another [32] and are formed through the contribu-
tion of several FO subunits (a, b, e, f, g, i/j, and k) [18].
3. Mitochondrial Uncoupling
Mitochondrial uncoupling is quite a general term and refers
to any pathway that enables proton reentry into the matrix
independent of ATP production. Indeed, the oxidative phos-
phorylation involves the coupling of redox reactions of the
respiratory chain to ATP synthesis by the F-ATP synthase
through a proton cycle across the IMM. These reactions,
however, are not fully coupled, since protons can return to
the mitochondrial matrix independent of ATP synthesis by
either unregulated endogenous pathways, termed basal pro-
ton leaks, which are indeed modifiable by drugs or by induc-
ible leaks through protein complexes (Figure 2). This energy-
dissipating cycling occurs in all eukaryotic cells and accounts
for a varying proportion of cellular metabolism, depending
on the tissue type [33].
Physiological uncoupling is typically mediated in mam-
mals by the finely regulated uncoupling protein 1 (UCP1),
an integral membrane protein of the brown adipose tissue
(BAT) that mediates the leak of protons across the IMM, dis-
sipating the proton gradient and inducing heat production
[34]. Physiological uncoupling also enables fine-tuning of
insulin secretion by uncoupling protein 2 (UCP2) in pancre-
atic β cells [35] and regulation of fatty acid metabolism by
uncoupling protein 3 (UCP3), which is specific to skeletal
muscle, BAT, and heart, although UCP2 and UCP3 functions
are not clearly established [33]. Moreover, multiple ATP-
dependent dissipative pathways exist in yeast mitochondria
that include both selective [36, 37] and unselective channels
[38]. In plants, besides UCPs [39], a further energy dissipa-
tion system has been described, called alternative oxidase
(AOX), which couples ubiquinol oxidation with direct reduc-
tion of oxygen to water [40].
Mitochondrial uncoupling can also be induced by chem-
ical uncouplers, i.e., small molecules that lessen the proton
motive force across the IMM. These molecules belong to
one of two general classes: protonophore uncouplers and
nonprotonophores. Protonophore uncouplers, such as car-
bonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP),
are lipophilic weak acids able to traverse the membrane as
an uncharged form, inducing complete uncoupling at very
low concentration, i.e., in the nM range, and causing sudden
increases of the respiratory rates that are oligomycin-
insensitive [41]. Nonprotonophores can instead activate
latent proton leaks to variable degrees through specific pro-
tein complexes that lead to mitochondrial dysfunction. Mito-
chondrial uncoupling can be measured directly as a decrease
in the electrochemical gradient or indirectly, as a decrease in
the phosphorylation efficiency, i.e., ADP/O stoichiometry,
or/and as a decrease of the respiratory control ratio (RCR),
i.e., the ratio between oxygen consumption during (state 3)
and after (state 4) ADP phosphorylation.
Mitochondrial uncoupling is not completely harmful.
Indeed, there is a close inverse relationship between increas-
ing the proton leak and ROS generation in isolated mito-
chondria [42]. It is long known that addition to isolated
mitochondria of uncouplers, as well as ADP, increases the
oxygen consumption and lowers the mitochondrial electro-
chemical gradient, decreasing ROS production [43]. Con-
versely, inhibition of the ATP synthase capacity leads to
accumulation of the electrons in the upstream complexes of
the respiratory chain, promoting oxidative stress and mito-
chondrial dysfunction [3], as recently observed in diabetic
cardiomyopathy in mice [44]. These observations support a
role for endogenous mitochondrial uncoupling in protection
against ROS production [2, 33]. Consistently, therapeutic
mitochondrial uncoupling is reported to be protective in a
variety of disorders, including obesity [45, 46], diabetes
[47, 48], ischemia/reperfusion injury [33, 49], Parkinson’s
disease [50], and aging [51], although the responsible factor(s)
remain to be fully understood. Mild uncoupling can be




Figure 1: Structure of the mitochondrial F-ATP synthase. Subunits
are shown in colors as follows. F1 is shown with the alternating α
(green) and β subunits (red). On the left, the peripheral stalk (PS)
includes the OSCP (yellow), b (dark blue), F6 (orange), and d
(pink) subunits. The central stalk (CS) connecting the α3β3
subcomplex to the c-ring composed of 8 identical subunit c
(purple) includes the γ (cyan), δ (blue), and ε (ice blue) subunits.
The FO membrane sector includes the subunits a (dark red, mostly
covered in the picture by other subunits), f (white), A6L (emerald,
mostly covered by other subunits), g (light orange), and e (silver).
In the membrane region, which is delineated by dotted lines, the
subunits e and g, with the N-terminal part of subunit b, create a
subdomain that bends the inner mitochondrial membrane.
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in obese diabetic mice, where UCP2 overexpression restored
the impaired endothelium-dependent relaxation [48], or by
the use of chemical uncouplers, such as niclosamide ethanol-
amine, which improved diabetic symptoms in mice [47], or
the novel mitochondrial uncoupler BAM15, which has no
off-target activity on other cellular membranes [52, 53]. Nev-
ertheless, caution is always required when targeting mito-
chondrial uncoupling via lipophilic weak acids, even when
they are selective, since, differently from the UCPs, their
activity lacks autoregulation, i.e., is not desensitized by reduc-
tion of the membrane potential [7].
4. F-ATP Synthase Uncoupling
The term F-ATP synthase uncoupling refers to any condition
that inhibits the coupling between the F1 catalytic activities
and the proton translocation by FO. Conditions that activate
the formation of a proton back-leak through FO indepen-
dently from the synthesis of ATP lead to dissipation of the
proton gradient, thus transforming F-ATP synthase into an
energy-dissipating enzyme. Indeed, the enzyme appears to
have an intrinsic robustness, as recently demonstrated by
the formation of stable incomplete subcomplexes after dis-
ruption of individual human genes for subunits in the FO
membrane portion [24]. However, the dissipative pathways
and their modulation are still to be defined in the majority
of cases. For example, mammalian mitochondrial oxidation
of mono- and dithiols located in FO induces a complete
uncoupling of ATP synthase, which is not reverted by oligo-
mycin [54]. The authors proposed that the lesion was on the
cytosolic side of the oligomycin block point of the proton
channel, a location that would suggest the involvement of
the unique conserved cysteine residue of the subunit c. More-
over, the formation of a disulphide bridge between two vici-
nal subunits b of two adjacent F-ATP synthase monomers
induces a severe oligomycin-insensitive uncoupling, of which
the molecular mechanism has not been fully elucidated [55].
Another latent oligomycin-insensitive proton-translocating
pathway in FO would comprise the subunits e, f, g, and
A6L, of which conductance was markedly increased upon
displacement of the matrix protein factor B from FO. This
effect is due to oxidation of vicinal thiols of factor B and is
parallel to mitochondrial uncoupling [56, 57]. More recently,
the matrix protein Bcl-XL has been identified in neurons as
able to revert ATP synthase uncoupling by binding to the β
subunit, although the underlying mechanism remains to be
established [58, 59]. Interestingly, the leucine-rich pentatri-
copeptide repeat containing protein (Lrpprc), a key posttran-
scriptional regulator of mtDNA expression defective in the
French Canadian type of Leigh syndrome, has also resulted
to be crucial for F-ATP synthase coupling by modulating
the proper assembly of the subunits OSCP and A6L. In the
Lrpprc conditional knockout mouse heart, decrease in ATP
production is due to the appearance of uncoupled subas-
sembled F-ATP synthase complexes, causing hyperpolariza-
tion and increase of mitochondrial ROS production, in
spite of an unaltered ADP/O ratio, thus showing the conse-
quences of F-ATP synthase assembly defects on mitochon-
drial bioenergetics [60].
F-ATP synthase uncoupling is also stimulated by a num-
ber of cationic dyes, namely, coriphosphine, Nile blue, pyro-
nin Y, and acridine orange, which increase both state 4
respiration and ATPase activity, but the binding sites remain






























Figure 2: The proton circuit across the inner mitochondrial membrane. During the oxidative phosphorylation, the redox reactions of the four
respiratory chain complexes are indirectly coupled to ATP synthesis by the F-ATP synthase dimers through the electrochemical proton
gradient across the IMM. Return of protons into the matrix independent of ATP synthesis through the basal leak pathway, or through
inducible leaks, decreases the electrochemical proton gradient and leads to mitochondrial uncoupling protecting mitochondria against
ROS production. Proton back-leaks through the FO sector of F-ATP synthase, independent of the synthesis of ATP, lead to dissipation of
the proton gradient, thus transforming F-ATP synthase into an energy-dissipating structure. Red arrows correspond to proton leaks.
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proton back-leak through the eukaryotic FO is 17β-estradiol
that, at micromolar concentrations, induces an “intrinsically
slipping state” of F-ATP synthase, while the enzyme is
actually catalysing ATP synthesis, therefore resulting in a
depressed RCR and ADP/O ratio [62]. Such partially
uncoupled state is promoted by ATP and reversed by oligo-
mycin, but not by resveratrol, supporting the fact that the
FO moiety is a site of action of 17β-estradiol. Possibly, a con-
formational change is transmitted to FO through the OSCP
subunit, which contains a binding site for 17β-estradiol able
to mediate the inhibition of ATPase activity both at nanomo-
lar and micromolar concentrations [63, 64]. The ability of
ATP to cause enzyme uncoupling seems conserved, since a
transition from a tightly coupled to a loosely coupled state
triggered by ATP binding is also described for bacterial
ATP synthase, although the underlying mechanism remains
to be elucidated [65, 66]. A complete uncoupling is instead
induced by addition of Ca2+, which, differently from Mg2+,
only sustains ATP hydrolysis by F1 that is not coupled to gen-
eration of a proton gradient in both prokaryotes [67] and
eukaryotes [68–70], in spite of Ca2+ ability to sustain the
F1 rotational catalysis [71]. These data strongly suggest that
the catalytic site has a different conformation state when
occupied by Ca2+ that, when compared with Mg2+, is unable
to couple the chemical catalysis to the generation of a pro-
ton gradient.
Based on these observations, it has been suggested that
Ca2+ binding, possibly by replacing Mg2+ at the catalytic site
[72], together with ROS could cause a drastic conformational
change to the ATP synthase dimer. This would give rise to
the formation of a high conductance channel, named perme-
ability transition pore (PTP), thus representing an extreme
form of enzyme uncoupling. The PTP is a nonselective chan-
nel modulated by Ca2+ and ROS and is located in the IMM,
and its opening implies the dissipation of the proton gradient
with cessation of ATP synthesis and maximization of ATP
hydrolysis. The PTP displays a range of conductance states,
which have been originally characterized by electrophysiol-
ogy in mammals [73]. Persistent PTP opening causes
equilibration of low-molecular-weight (<1500Da) molecules
across the IMM, which disrupts any metabolic gradient,
followed by an osmotic stress leading to matrix swelling
and, eventually, to OMM rupture and release of proapoptotic
factors like cytochrome c, endonuclease G, and AIF. Indeed,
the PTP is causally involved in cell death in several diseases,
and the most documented cases include heart ischemia, mus-
cular dystrophies, and neurodegenerative diseases [74].
The involvement of F-ATP synthase in PTP formation
has been supported by (i) genetic manipulation of selected
enzyme subunits whose ablation affected the PTP function
[75, 76]; (ii) electrophysiological measurements, which
showed that the PTP generated by F-ATP synthase is charac-
terized by a variety of conductances similar to those of the
native pore [77, 78]; and (iii) mutagenesis of specific residues
of F-ATP synthase within F1 [72] or FO [79–81]. In particu-
lar, OSCP, located on top of F-ATP synthase, appears ideally
suited to transmit Ca2+-dependent conformational changes
from F1 to the rigid peripheral stalk causing pore formation
within the F-ATP synthase membrane portion, probably at
the interface between the two monomers forming an F-
ATP synthase dimer. Indeed, this model is strongly sup-
ported by the observations that OSCP (i) is the binding site
of cyclophilin (CyP) D, the best characterized PTP inducer,
which sensitizes the PTP to the effects of matrix Ca2+
and is released by cyclosporin A resulting in PTP inhibi-
tion [77, 82]; (ii) is the binding site of the immunomodula-
tory drug benzodiazepine (Bz) 423 [83], which like CyPD
acts as a PTP inducer [77]; (iii) contains a highly conserved
histidyl residue (H112 in the human mature protein) respon-
sible for the inhibitory effect of acidic matrix pH on the PTP
[81]; (iv) undergoes, in contrast to major subunits of the
ATP synthase complex, a selective decrease of its expression
level, which is concomitant with CyPD upregulation and
PTP activation in brain mitochondria from aging mice [84];
and (v) interacts with the β amyloid protein in cultured
neurons, leading to PTP sensitization, and in the brain of
individuals with Alzheimer’s disease, potentially mediating
mitochondrial impairment [85]. Nevertheless, the Ca2+- and
ROS-dependent long-range conformational changes that could
be responsible for the PTP formation in the FO sector remain
to be defined. Moreover, other models of PTP have been
advanced that hypothesize the PTP resides in the c-ring of
ATP synthase [76, 79] or, alternatively, in some other mito-
chondrial components not involving ATP synthase [86] so
that its molecular nature is still a matter of debate [25].
5. F-ATP Synthase as a Target for
Drug Development
Until now, malfunction of F-ATP synthase has been associ-
ated with a variety of pathological conditions, such as cardio-
vascular [87] and neurodegenerative diseases [88], obesity
and type 2 diabetes [89, 90], and cancer [91]. Despite such
important evidence, F-ATP synthase has only recently been
used as an effective drug target for disease conditions and
for the regulation of energy metabolism [92], despite the fact
that more than 300 natural and synthetic molecules are
known to bind and inhibit this complex [93]. Moreover, the
recent finding that F-ATP synthase is involved in PTP for-
mation may make this complex a viable target for future
therapy in a variety of diseases [25]. Selective interaction of
F-ATP synthase with some drugs has been identified. For
example, the enzyme is recognized as a molecular target of
the cytotoxic agent apoptolidin, which induces apoptosis in
human cancer cell lines by binding to the FO subunit a and
inhibiting the enzyme activity [94]. Another example is pro-
vided by the immunomodulatory drug Bz 423, which acti-
vates the mitochondrial pathway of apoptosis selectively in
pathogenic lymphocytes [83]. More recently, the α subunit
of the F1 sector has been recognized as a target for the drug
candidate J147, which shows therapeutic efficacy in several
mouse models of Alzheimer’s disease. By targeting ATP
synthase, J147 causes an increase in intracellular Ca2+ leading
to activation of the AMPK/mTOR pathway, a canonical lon-
gevity mechanism [95]. Moreover, the enzyme is a very
promising molecular target for the development of new anti-
microbial agents that selectively inhibit the bacterial F-ATP
synthases, such as bedaquiline that represents the first
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compound of a new class of potent antituberculosis drugs
[96]. Attention has recently focused on dietary phytochemi-
cals with antimicrobial properties, a variety of which inhibits
the bacterial F-ATP synthase to a variable degree depending
on the type and positioning of the functional groups. Both F1
and FO subunits have been identified as contributing to the
binding sites for such inhibitors [92]. Because dietary phyto-
chemicals also inhibit the mitochondrial F-ATP synthase
[97], attempts are being made to modify the functional
groups of these compounds, making them more potent and
selective inhibitors of the bacterial ATP synthases [92]. On
the other hand, many of these phytochemicals exhibit diverse
activities, such as antioxidant, anticancerogenic, and anti-
obesity actions [97]. An example is resveratrol, a well-
characterized inhibitor of the mitochondrial F-ATP synthase
whose binding site is located between the C-terminal part of
the γ subunit and the βTP subunit [98]. Resveratrol also
increases the basal energy expenditure and thermogenesis,
along with alteration of numerous signalling pathways that
converge on the mitochondria [99].
Recently, there has been an increased interest in the use
of essential oils (EOs) as preventive and therapeutic agents
for treatment of various diseases, including obesity [100].
EOs are secondary metabolites of plants representing a mix-
ture of a variety of volatile molecules such as terpenoids and
phenol-derived aromatic and aliphatic components. EOs also
possess antimicrobial, anti-inflammatory, anticancer, and
antioxidant properties, but the molecular targets are still to
be defined in the majority of cases [101]. The EO component
D-limonene, which is recognized as a potential chemothera-
peutic agent [102], induces apoptosis via the mitochondrial
pathway in several human cell lines [103] and has also anti-
obesity activity, mainly by induction of the brown fat-like
phenotype in white adipocytes [104]. Interestingly, the
EO component p-cymene directly induces a mild uncou-
pling of F-ATP synthase, leading to an ATP-stimulated,
oligomycin-sensitive proton leak through the FO moiety
that decreases the electrochemical gradient and the respira-
tory control ratio but not the ADP/O ratio [105]. Such prop-
erties might suggest its use as a pharmacological agent to
decrease the metabolic efficiency. However, caution is
required, because affecting all mitochondria throughout the
body may be a high-risk treatment, as energy homeostasis
may be compromised in tissues such as the heart and brain.
6. Conclusions
The existence of several conditions that inhibit or abolish the
coupling between F1 and FO clearly indicates that the energy-
conserving enzyme can transform into an energy-dissipating
structure within the IMM. Available structures of the fully
coupled F-ATP synthase do not display obvious features
that can accommodate these dissipative pathways. Indeed,
the molecular definition of the pathways responsible for F-
ATP synthase uncoupling and of its potential regulators still
represents a research challenge in bioenergetics. Due to the
central role of F-ATP synthase in cellular metabolism, this
definition is crucial and potentially useful for therapy in a
variety of diseases.
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